Cargando…
Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
There is currently no effective treatment for pancreatic ductal adenocarcinoma (PDAC). While palliative chemotherapy offers a survival benefit to most patients, nearly all will eventually progress on treatment and long-term survivability remains poor. Given the lack of subsequent line treatment opti...
Autores principales: | Principe, Daniel R., Aissa, Alexandre F., Kumar, Sandeep, Pham, Thao N. D., Underwood, Patrick W., Nair, Rakesh, Ke, Rong, Rana, Basabi, Trevino, Jose G., Munshi, Hidayatullah G., Benevolenskaya, Elizaveta V., Rana, Ajay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170157/ https://www.ncbi.nlm.nih.gov/pubmed/35476525 http://dx.doi.org/10.1073/pnas.2200143119 |
Ejemplares similares
-
The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
por: Principe, Daniel R., et al.
Publicado: (2021) -
Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer
por: Principe, Daniel R., et al.
Publicado: (2022) -
An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015) -
Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
por: Pham, Thao N. D., et al.
Publicado: (2021) -
Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer
por: Kumar, Sandeep, et al.
Publicado: (2020)